Suzanne Egyhazi Brage

Publikationer
Forskningsbidrag
Populärvetenskap och samverkan

Artiklar

Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930
Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and Tolerability
Backlund E; Grozman V; Brage SE; Lewensohn R; Lindberg K; Helgadottir H
Article: CANCERS. 2022;14(15):3587
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hoiom V; Brage SE
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: ACTA ONCOLOGICA. 2022;61(1):14-21
A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma
Falkenius J; Keskitalo J; Kanter L; Johansson H; Hoiom V; Hansson J; Brage SE
Article: GENETICS IN MEDICINE. 2022;24(1):157-169
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
Yang M; Johnsson P; Brautigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engstrom PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Hoiom V
Article: SCIENTIFIC REPORTS. 2021;11(1):11023
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
Article: CANCER RESEARCH. 2021;81(9):2545-2555
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Karlsson MJ; Svedman FC; Tebani A; Kotol D; Hoiom V; Fagerberg L; Edfors F; Uhlen M; Brage SE; Maddalo G
Article: CELL DEATH & DISEASE. 2020;11(10):882
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
Das I; Chen H; Maddalo G; Tuominen R; Rebecca VW; Herlyn M; Hansson J; Davies MA; Brage SE
Article: MELANOMA RESEARCH. 2020;30(5):443-454
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
Vidarsdottir L; Fernandes RV; Zachariadis V; Das I; Edsbacker E; Sigvaldadottir I; Azimi A; Hoiom V; Hansson J; Grander D; Egyhazi Brage S; Pokrovskaja Tamm K
Article: CELL DEATH AND DIFFERENTIATION. 2020;27(7):2081-2098
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Das I; Gad H; Braeutigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Rajagopal V; Hansson J; Helleday T; Brage SE; Berglund UW
Article: CELL DEATH & DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: MOLECULAR SYSTEMS BIOLOGY. 2018;14(3):e7858
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi A; Caramuta S; Seashore-Ludlow B; Bostrom J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Brage SE; Altun M; Uhlen M; Maddalo G
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELLULAR ONCOLOGY. 2017;40(6):631-638
ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Article: CELL DEATH & DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: BMC CANCER. 2017;17(1):584
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
Falkenius J; Johansson H; Tuominen R; Stolt MF; Hansson J; Brage SE
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: CELL REPORTS. 2016;15(9):2000-2011
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Georgoudaki A-M; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Ostling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MCI
Article: CLINICAL CANCER RESEARCH. 2016;22(1):146-157
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Kimbung S; Johansson I; Danielsson A; Veerla S; Brage SE; Stolt MF; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmstrom P-O; Soderberg M; Walz TM; Ferno M; Hatschek T; Hedenfalk I
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(12):2844-2853
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Johansson CH; Linden D; Johansson H; Stolt MF; Walker C; Snowden H; Newton-Bishop J; Hansson J; Brage SE
Article: ANNALS OF ONCOLOGY. 2015;26(1):81-88
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2014;24(8):1389-1394
Metabolic Markers and HSP60 in Chemonaive Serous Solid Ovarian Cancer Versus Ascites
Hjerpe E; Brage SE; Stolt MF; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MATRIX BIOLOGY. 2014;38:69-83
Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146)
Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Brage SE; Hansson J; Patarroyo M
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Azimi A; Pernemalm M; Stolt MF; Hansson J; Lehtio J; Brage SE; Johansson CH
Journal article: ANNALS OF ONCOLOGY. 2014;25:i5
12O Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival
Tobin NP; Harrell JC; Brage SE; Stolt MF; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: MELANOMA RESEARCH. 2013;23(6):452-460
High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Brage SE
Article: BMC CLINICAL PATHOLOGY. 2013;13(1):30
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.
Hjerpe E; Egyhazi Brage S; Carlson J; Frostvik Stolt M; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MELANOMA RESEARCH. 2013;23(5):360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Johansson CH; Azimi A; Stolt MF; Shojaee S; Wiberg H; Grafstrom E; Hansson J; Brage SE
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(3):448-455
HSP60 Predicts Survival in Advanced Serous Ovarian Cancer
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(12):2809-2817
High Frequency of p16 ^INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson A; Tuominen R; Grafstrom E; Hansson J; Egyhazi S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(8):2062-2070
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta S; Egyhazi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui W-O
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: PIGMENT CELL & MELANOMA RESEARCH. 2009;22(2):196-204
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Hoiom V; Tuominen R; Kaller M; Linden D; Ahmadian A; Mansson-Brahme E; Egyhazi S; Sjoberg K; Lundeberg J; Hansson J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(4):526-534
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu L-A; Zerba KE; Lee H; Clark E; Galbraith S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(11):2696-2704
Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
Jovanovic B; Kroeckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
Article: MOLECULAR CANCER THERAPEUTICS. 2008;7(9):2876-2883
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Smalley KSM; Lioni M; Palma MD; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Article: CANCER RESEARCH. 2007;67(19):9006-9012
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: MELANOMA RESEARCH. 2006;16(6):471-478
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Edlundh-Rose E; Egyhazi S; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Article: CLINICAL CHEMISTRY. 2005;51(12):2388-2391
Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing
Käller M; Tuominen R; Ahmadian A; Magnusson V; Egyhazi S; Hansson J; Lundeberg J
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: BREAST CANCER RESEARCH. 2005;7(6):R953-R964
Gene expression profiling spares early breast cancer patients from adjuvant therapy:: derived and validated in two population-based cohorts
Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523
O⁶-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: HUMAN MUTATION. 2002;20(5):408-409
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019
Immunohistochemical analysis of DNA mismatch repair protein and O⁶-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342
Analysis of O⁶-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: CARCINOGENESIS. 1997;18(10):1889-1895
O-6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro
Liu Y; Egyhazi S; Hansson J; Bhide SV; Kulkarni PS; Grafstrom RC
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452
Role of O-6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line
Egyhazi S; Edgren MR; Hansson J; Krockel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134
Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases
Egyhazi S; Margison GP; Hansson J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(13):2319-2326
Analysis of O-6 methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
Hansson J; Martenhed G; Egyhazi S; Tani E; Platz A
Article: ACTA ONCOLOGICA. 1996;35(6):683-690
Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency
Hansson J; Edgren MR; Egyhazi S; Hao XY; Mannervik B; Ringborg U
Article: ANTI-CANCER DRUGS. 1995;6(5):657-668
APOPTOSIS AND C-JUN INDUCTION BY CISPLATIN IN A HUMAN-MELANOMA CELL-LINE AND A DRUG-RESISTANT DAUGHTER CELL-LINE
ZHAO R; RABO YB; EGYHAZI S; ANDERSSON A; EDGREN MR; LINDER S; HANSSON J
Journal article: CANCER RESEARCH. 1993;53(18):4257-4261
CONTRIBUTION OF GLUTATHIONE TRANSFERASE M3-3 TO 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA RESISTANCE IN A HUMAN NONSMALL CELL LUNG-CANCER CELL-LINE
BERHANE K; HAO XY; EGYHAZI S; HANSSON J; RINGBORG U; MANNERVIK B
Journal article: EUROPEAN JOURNAL OF CANCER. 1991;27(12):1658-1662
CARMUSTINE-INDUCED TOXICITY, DNA CROSS-LINKING AND O6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY IN 2 HUMAN LUNG-CANCER CELL-LINES
EGYHAZI S; BERGH J; HANSSON J; KARRAN P; RINGBORG U
Visa fler

Alla övriga publikationer

Conference publication: ANNALS OF ONCOLOGY. 2023;34:S688-S689
Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(9):1116-1120
Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy
Costa Svedman F; Jalsenius M; Grozman V; Bergqvist M; Soderdahl F; Rotstein S; Ny L; Egyhazi Brage S; Helgadottir H
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S945
Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma
Svedman FC; Helgadottir H; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2022;142(3 PT A):736-740.e6
Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma
Das I; Tuominen R; Helleday T; Hansson J; Berglund UW; Brage SE
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):9556
Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.
Helgadottir H; Svedman FC; Jalsenius M; Hoiom V; Rotstein S; Brage SE; Grozman V; Soderdahl F; Ny L; Bergqvist M
Preprint: BIORXIV. 2020
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grandér D; Brage SE; Johnsson P
Conference publication: ANNALS OF ONCOLOGY. 2019;30:xi8-xi9
27P Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)
Svedman FC; Yang M; Tuominen R; Brage SE; Höiom V
Meeting abstract: ANNALS OF ONCOLOGY. 2019;30:vii8
Therapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma
Das I; Gad H; Brautigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Hansson J; Helleday T; Brage SE; Berglund UW
Conference publication: ANNALS OF ONCOLOGY. 2019;30:v559
1369P Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hansson J; Höiom V; Brage SE
Meeting abstract: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2019;139(9):s298
Elucidate the underlying molecular mechanisms of the combination treatment effects of Afatinib (EGFR/HER2 inhibitor) and Crizotinib (MET inhibitor) in cutaneous malignant melanoma (CMM)
Das I; Chen H; Maddalo G; Wilhelm M; Tuominen R; Hoiom V; Hansson J; Davies M; Brage S
Conference publication: ANNALS OF ONCOLOGY. 2019;30
Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)
Svedman FC; Yang M; Tuominen R; Brage SE; Holom V
Conference publication: ANNALS OF ONCOLOGY. 2019;30:559
Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hansson J; Hoiom V; Brage SE
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a14
Surgical removal of metastatic lesions increases T-cell reactivity to tumor-associated antigens in stage III melanoma patients
de Coana YP; Gunnarsdottir FB; Wolodarski M; Brage SE; Masucci G; Hansson J; Kiessling R
Meeting abstract: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2018;138(5):S200
Effects of MTH1 inhibitor TH1579 on cutaneous melanoma
Das I; Gad H; Pudelko L; Brautigam L; Tuominen R; Helleday T; Hansson J; Brage S; Berglund U
Conference publication: ANNALS OF ONCOLOGY. 2017;28:v437
1232P Investigation of AMBRA1 as a melanoma susceptibility gene
Hoeiom V; Yang M; Nosrati K; Azimi A; Brage SE; Tuominen R
Conference publication: CANCER RESEARCH. 2017;77:p1-07-16-p1-07-16
Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients
Tobin NP; Lundberg A; Lindstrom LS; Harrell JC; Brage SE; Stolt MF; Einbeigi Z; Loman N; Malmberg M; Perou CM; Bergh J; Hatschek T
Conference publication: ANNALS OF ONCOLOGY. 2017;28
Investigation of AMBRA1 as a melanoma susceptibility gene
Hoeiom V; Yang M; Nosrati K; Azimi A; Brage SE; Tuominen R
Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(9):s245
500 Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma
Lohcharoenkal W; Svedman FC; Sonkoly E; Brage SE; Hansson J; Pivarcsi A; Eriksson H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):9579
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).
Eriksson H; Lohcharoenkal W; Costa-Svedman F; Sonkoly E; Brage SE; Hansson J; Pivarcsi A
Conference publication: CANCER RESEARCH. 2016;76:B28
PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts clinical outcome in melanoma patients
Vidarsdottir L; Azimi A; Serviss J; Ingvar C; Jonsson G; Olsson H; Stolt MF; Hansson J; Brage SE; Grander D; Johnsson P
Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(9):S245
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma
Lohcharoenkal W; Svedman FC; Sonkoly E; Brage SE; Hansson J; Pivarcsi A; Eriksson H
Conference publication: CANCER RESEARCH. 2015;75:p6-08-03-p6-08-03
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer
Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi S; Bergh J; Einbeigi Z; Linderholm B; Lidbrlnk E; Loman N; Malmstroem P; Soederberg M; Walz TM; Fernoe M; Hatschek T; Hedenfalk I
Review: PHARMACOLOGY & THERAPEUTICS. 2014;142(2):176-182
BRAF inhibitors in cancer therapy
Johansson CH; Brage SE
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(1):287-290
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Johansson CH; Hoiom V; Jonsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Brage SE; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2012;48:43
Unraveling BRAF Inhibitor (PLX4032) Resistance Mechanisms
Azimi A; Johansson CH; Pernemalm M; Touminen R; Lehtio J; Hansson J; Egyhazi S
Conference publication: ANNALS OF ONCOLOGY. 2012;23:v27
P2.17 Proteomics and Gene Expression Profiling of Melanoma Chemotherapy Response in Tumors
Johansson CH; Azimi A; Pernemalm M; Pawitan Y; Stolt MF; Lazar V; Lundeberg J; Lehtiö J; Egyhazi S; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:v23
P2.04 Effects of Combined Exposure To Braf and Pi3K Inhibitors With Chemotherapeutic Agents
Egyhazi S; Azimi A; Ghasghgaei S; Stolt MF; Johansson CH; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:27
PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA CHEMOTHERAPY RESPONSE IN TUMORS
Johansson CH; Azimi A; Pernemalm M; Pawitan Y; Stolt MF; Lazar V; Lundeberg J; Lehtio J; Egyhazi S; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:23
EFFECTS OF COMBINED EXPOSURE TO BRAF AND PI3K INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS
Egyhazi S; Azimi A; Ghasghgaei S; Stolt MF; Johansson CH; Hansson J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):8551
A gene expression profile associated with clinical outcome in stage III melanoma.
Falkenius J; Lindberg J; Johansson H; Frostvik-Stolt M; Lundeberg J; Hansson J; Egyhazi S
Conference publication: CANCER RESEARCH. 2011;71:3495
Targeted therapies in melanoma - in vitro effects of single and combined drug treatment
Azimi A; Egyhazi S; Johansson C; Hansson J
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(2):618-620
Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Scarra GB; Hayward NK; Hansson J
Conference publication: CANCER RESEARCH. 2009;69
Investigating the role of microRNA-211 in the pathogenesis of metastatic melanoma
Caramuta S; Egyhazi S; Rodolfo M; Hansson J; Catharina L; Lui W-O
Review: MOLECULAR ONCOLOGY. 2008;1(4):395-405
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
Platz A; Egyhazi S; Ringborg W; Hansson J
Conference publication: PIGMENT CELL & MELANOMA RESEARCH. 2008;21(2):285
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma
Hansson J; Jovanovic B; Krockel D; Linden D; Nilsson B; Egyhazi S
Conference publication: ANNALS OF ONCOLOGY. 2008;19:243
SHARED REGIONS OF DECREASED DNA COPY NUMBERS IN NRAS AND BRAF MUTATED MELANOMAS
Jovanovic B; Egyhazi S; Hansson J
Corrigendum: CANCER RESEARCH. 2008;68(4):1245
The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Conference publication: MELANOMA RESEARCH. 2007;17(1):a10-a11
INV 22 Drug resistance mechanisms
Egyhazi S
Conference publication: MELANOMA RESEARCH. 2007;17(1):a1-a2
INV 3 Molecular genetics of melanoma predisposition
Hansson J; Magnusson V; Tuominen R; Egyházi S; Linden D
Conference publication: MELANOMA RESEARCH. 2007;17(1):a18-A19
P-03 CCND1 A870G polymorphism and age of onset of melanoma
Egyházi S; Platz A; Grafström E; Tuominen R; Magnusson V; Hansson J
Conference publication: MELANOMA RESEARCH. 2007;17(1):a17-a18
P-02 NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
Egyházi S; Edlundh-Rose E; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Conference publication: MELANOMA RESEARCH. 2007;17(1):a21-a22
P-11 Methylation of the O6 methylguanine-DNA methyltransferase promoter in melanoma tumors in relation to chemotherapy
Ma S; Edlundh-Rose E; Hansson J; Egyházi S
Conference publication: MELANOMA RESEARCH. 2006;16(Supplement 1):s26
Association of melanoma risk with phenotype and MC1R genotype in the Swedish population
Magnusson V; Tuominen R; Käller M; Månsson-Brahme E; Ahmadian A; Egyhazi S; Linden D; Sjöberg K; Lundeberg J; Hansson J
Conference publication: MELANOMA RESEARCH. 2006;16(Supplement 1):s61-s62
Amplification of the cyclin D1 locus 11q13 in melanoma metastases: association to cyclin D1 protein expression
Tuominen R; Grafström E; Egyhazi S
Conference publication: CANCER RESEARCH. 2006;66(8)
Array comparative genomic hybridization (aCGH)-based support vector machines used to determine genetic aberrations that correlate with either BRAF or NRAS mutations in melanoma tumors and cell lines
Zaks TZ; Greshock JD; Medina CA; Ward R; Egyhazi S; Nathanson K; Weber BL
Conference publication: CANCER RESEARCH. 2006;66(8)
Methylation status of the MGMT promoter in melanoma tumors in relation to protein expression and clinical response to chemotherapy
Ma S; Edlundh-Rose E; Hansson J; Lundeberg J; Egyhazi S
Conference publication: MELANOMA RESEARCH. 2004;14(4):a21-a22
P-15 Activating NRAS or BRAF mutations in combination with INK4 deletions are common in melanoma tumors
Hansson J; Grafström E; Omholt K; Egyházi S; Ringborg U; Platz A
Conference publication: MELANOMA RESEARCH. 2004;14(4):a11
24 Mutational analysis and gene expression profiling in malignant melanoma: implications for therapy
Hansson J; Huang F; Mashyekhi K; Omholt K; Jovanovic B; Sakko AJ; Egyhazi S; Frostvik M; Shaw P; Ringborg U
Letter: CLINICAL CHEMISTRY. 2004;50(5):975-976
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies
Egyházi S; Bjöhle J; Skoog L; Huang F; Borg AL; Stolt MF; Hägerström T; Ringborg U; Bergh J
Conference publication: BREAST CANCER RESEARCH AND TREATMENT. 2002;76:S29
Microarray studies on a population based breast cancer cohort - search for gene profiles with prognostic and predictive value.
Bjohle J; Pawitan Y; Skoog L; Shaw P; Amler L; Humphreys K; Huang F; Egyhazi S; Borg AL; Hagerstrom T; Wedren S; Sandelin K; Hall P; Bergh J
Conference publication: AMERICAN JOURNAL OF HUMAN GENETICS. 2001;69(4):418
Novel O6-methylguanine-DNA methyltransferase single nucleotide polymorphisms (SNPs) detected among healthy individuals from the Swedish normal population.
Platz A; Ma S; Smoczynski K; Hansson J; Ringborg U; Egyhazi S
Conference publication: MELANOMA RESEARCH. 1999;9(3):329
P16 Novel polymorphisms in codons 143 and 178 in the O6-methylguanine-DNA methyltransferase gene in malignant melanoma
Egyházi S; Platz A; Smoczynski K; Ringborg U
Conference publication: MELANOMA RESEARCH. 1997;7(Supplement 1):s115
Analysis of O6-methylguanine-DNA methyltransferase in fine needle biopsies of human melanoma metastases
Hansson J; Egyhazi S; Margison G; Ringborg U
Conference publication: MELANOMA RESEARCH. 1997;7(2):161
17 Drug resistance factors in malignant melanoma
Hansson J; Egyházi S; Jungnelius U; Ringborg U
Thesis / dissertation: 1996
Studies of resistance factors against chloroethylnitrosourea drugs in malignant tumor cells
Egyházi, Suzanne
Other: BRITISH JOURNAL OF CANCER. 1995;71(1):37-39
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITIES IN BIOPSIES OF HUMAN-MELANOMA TUMORS
EGYHAZI S; HANSSON J; RINGBORG U
Visa fler

Forskningsbidrag

Translationella studier av malignt melanom
Konung Gustaf V:s Jubileumsfond
1 January 2021 - 31 December 2022
Translationella studier av malignt melanom
Konung Gustaf V:s Jubileumsfond
1 January 2018 - 31 December 2020
Kliniska och molekylärgenetiska studier av malignt melanom
Konung Gustaf V:s Jubileumsfond
1 January 2015
Molecular predictive factors for durable response of drugs targeting the MAPK pathway in melanoma
Swedish Research Council
1 January 2014 - 31 December 2016
Undersöka effekten av inflammationsproteiner på kliniskt utfall vid behandling med anti-PD1 vid metastaserande hudmelanom
Karolinska Institutet
Ny strategi för målsökande kombinationsbehandling mot EGFR/HER2 och MET vid malignt melanom
Karolinska Institutet

Artiklar

Alla övriga publikationer

Forskningsbidrag

Nyheter från KI

Kalenderhändelser från KI